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Abstract This article presents a tool to calculate health
care costs attributable to overweight in a comparable and
standardized way. The purpose is to describe the method-
ological principles of the tool and to put it into use by
calculating and comparing the costs attributable to over-
weight for The Netherlands, Germany and Czech Republic.
The tool uses a top-down and prevalence-based approach,
consisting of five steps. Step one identifies overweight-
related diseases and age- and gender-specific relative risks.
Included diseases are ischemic heart disease, stroke,
hypertension, type 2 diabetes mellitus, colorectal cancer,
postmenopausal breast cancer, endometrial cancer, kidney
cancer and osteoarthritis. Step two consists of collecting
data on the age- and gender-specific prevalence of these
diseases. Step three uses the population-attributable prev-
alence to determine the part of the prevalence of these
diseases that is attributable to overweight. Step four cal-
culates the health care costs associated with these diseases.
Step five calculates the costs of these diseases that are
attributable to overweight. Overweight is responsible for
20–26 % of the direct costs of included diseases, with
sensitivity analyses varying this percentage between
15–31 %. Percentage of costs attributable to obesity and
preobesity is about the same. Diseases with the highest
percentage of costs due to overweight are diabetes, endo-
metrial cancer and osteoarthritis. Disease costs attributable
to overweight as a percentage of total health care expen-
ditures range from 2 to 4 %. Data are consistent for all
three countries, resulting in roughly a quarter of costs of
included diseases being attributable to overweight.
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Introduction
The prevalence of overweight (BMI C 25 kg/m2) and
obesity (BMI C 30 kg/m2) is rapidly increasing in the
WHO European Region. In 2008/2009, the prevalence of
overweight in 19 European Union member states varied
between 51 and 69 % for men and between 37 and 57 %
for women [1]. If recent trends continue unabated, in 2030
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there will be 2.16 billion overweight and 1.12 billion obese
individuals worldwide [2]. Obesity is one of the WHO
Regional Office for Europe’s top priorities and the minis-
terial conference on nutrition in November 2006 in Istanbul
therefore completely focused on obesity [3].
Overweight is associated with increased risks for several
chronic diseases, especially type 2 diabetes mellitus, car-
diovascular diseases and musculoskeletal disorders [4].
Obesity at age 40 has been shown to reduce life expectancy
by 7 years in women and 6 years in men [5]. The increased
prevalence of chronic diseases that are partially due to
overweight causes a large burden on the health care system
and is associated with considerable health care costs.
Quantification of the amount of health care costs attribut-
able to overweight contributes to increased political
awareness to take action against it. Previous research in
various countries showed that between 2 and 5 % of annual
health care costs are attributable to overweight [6–11].
However, several reviews on the cost of illness attributable
to overweight show that, due to different methods for
calculation of these costs, the results are often not mutually
comparable between countries [10, 12, 13]. Furthermore,
several of these methods require data that are not generally
available. Therefore, the WHO regional office for Europe
commissioned the Dutch National Institute for Public
Health and the Environment (RIVM) to develop a meth-
odology for estimating the costs attributable to overweight
in a standardized way and to implement this in a software
tool (the OBCOST tool). The methodology should make
use of data that are generally available for most countries.
The purpose of this article is to describe this software
tool and methodological principles behind it. Furthermore,
the tool is put into use by calculating and comparing the
costs attributable to overweight among three European
countries, i.e., The Netherlands (NL), Germany (GE) and
Czech Republic (CZR).
Methods and procedures
Methodology of the OBCOST tool
The OBCOST tool uses a top-down, prevalence-based
approach, answering the question: what current (annual)
health care costs would have been avoided if overweight
had been eliminated in the past? The general framework of
the tool consists of five steps, which are shown in Fig. 1.
Below, each step will be described shortly. Background
information on the methodology and OBCOST tool can be
found in Online Resource 1.
In step one, diseases are identified that are related to
overweight, and age- and gender-specific relative risks are
assessed. For pragmatic reasons, this study uses the WHO
Comparative Quantification of Health Risks [4] where the
following diseases are estimated to be associated with
overweight: ischemic heart disease (IHD) (ICD-10: I20–
I25), stroke (ICD-10: I60–I69), hypertensive disease (ICD-
10: I10–I13), type II diabetes mellitus (ICD-10: E11),
colorectal cancer (ICD-10: C18–C21), postmenopausal
breast cancer (ICD-10: C50), endometrial cancer (ICD-10:
C54–C55), kidney cancer (ICD-10: C64–68) and osteoar-
thritis (ICD-10: M15–M19). The age- and gender-specific
relative risks that were entered in the tool consist partly of
relative risks given by the WHO in their Comparative
Quantification of Health Risks and partly of relative risks
as used by the RIVM in their chronic disease modelling
(see Online Resource 2).
Step two consists of collecting data on the age- and
gender-specific prevalence of these diseases [pd(a, g)].
These pd(a, g) data are assumed to be available from sur-
veys or morbidity registers, or they can be calculated (by
the OBCOST tool) from incidence data and disease-spe-
cific mortality using an incidence-prevalence-mortality
(IPM) model [14]. The latter is especially relevant for
diseases, such as cancers, where incidence data are more
readily available than prevalence data. Furthermore, in this
step collection of prevalence data for preobesity (BMI
25\ 30 kg/m2) and obesity (BMI[ 30 kg/m2) is required.
The third step determines the part of the prevalence of
the included diseases that is attributable to overweight. The
population-attributable prevalence (PAP) is used instead of
the population-attributable risk (PAR) since for chronic
diseases health care costs are (mostly) related to the
number of prevalent cases in a population and not to the
number of incident cases. Therefore, prevalence rates will
provide a more comprehensive estimation of costs than
incidence rates. Furthermore, the PAP takes into account
that risk factors and their relative risks can change over
time, as opposed to the PAR. The part of a disease that can
be attributed to overweight can be defined using the fol-
lowing formula:
Step 1: Identification of diseases and relative risks
Step 2: Determine prevalence of diseases
Step 3: Determine which part of the diseases is due to overweight
Step 4: Determine costs of the diseases
Step 5: Calculate costs due to overweight
Fig. 1 General framework of the OBCOST methodology
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PAPdða, g) ¼ pdða; gÞ  pdða; gjoverweight ! normalÞ
pdða, g)
where pd(a, g) is the prevalence of disease d for age group a
and gender g and pd(a, g |overweight ? normal) is the
prevalence of disease d for age group a and gender g in a
situation when all overweight persons would have had a
normal weight. The PAP is determined by back calculation
of past incidence rates from prevalence rates and disease-
specific mortality rates using the IPM (incidence-pre-
valence-mortality) model [14]. Then, relative risks are used
to calculate what the past incidence rates would have been
in a population without overweight. These past incidence
rates are calculated back to current prevalence rates in a
hypothetical population without overweight, and then the
PAP is found from the difference between these hypo-
thetical prevalence rates and the observed prevalence rates.
For a more detailed description of this method, see Online
Resource 1.
Step four calculates the health care costs associated
with the included diseases [cd(a, g)]. The method uses a
top-down approach for estimating the cost of illness,
which consists of four stages [15, 16]. First, total health
care costs of different health care providers are calcu-
lated. Second, information on health care utilization is
collected for each health care provider from patient
registers or surveys. These data should contain infor-
mation on health care use by the included diseases for
each provider, and if possible, information should be
stratified by age and gender. Third, allocation keys
need to be identified for each health care provider.
These allocation keys define the resource use by each
disease. In the last stage, all information is combined,
where total costs per provider are allocated to diseases.
The cost of illness for all providers is summed up,
which results in the final cost of illness estimation for
each disease by age and gender, cd(a, g). In order to
assure international comparability of cost of illness
estimations, the use of a standardized health accounting
framework is required. The OECD System of Health
Accounts (SHA) is recommended, restricting costs to
curative care [17].
Finally, the fifth step calculates the costs attributable to








cdða; gÞpdða; gÞPAPdða; gÞ
using the appropriate PAPd value for each disease. The
tool provides results in both absolute costs of included
diseases that are attributable to overweight and per-
centage of costs of included diseases that are attributable
to overweight.
Data collection for the three countries and data
treatment
In order to perform calculations for NL, GE and CZR, data
from these three countries were collected for population
numbers, BMI prevalence, mortality of diseases, disease
prevalence/incidence and costs of diseases. If possible,
collected data were age and gender specific (5-year age
groups were used). Data were not always complete for all
age categories. Since the OBCOST software does not work
when one or more cells are incomplete, estimations were
made for missing data. Detailed information on the col-
lected data and assumptions made is provided in Online
Resource 3.
The most important assumptions are presented here in
short. First, GE reported their population numbers of the
eldest ages as an aggregate group (90?). This number was
divided over the last three original age categories (90–94,
95–99, 100?) according to the WHO world standard
population distribution [18]. Second, for all countries,
prevalence, mortality and cost data were sometimes
reported in aggregate age groups as well. For prevalence
and mortality data, it was assumed that the rate provided
for the aggregate age group could be applied to all original
age groups within this aggregate age group. For cost data,
the number provided for the aggregate age group was
divided by the number of original age groups within the
aggregate age group, and this result was applied to all
original age groups within this aggregate age group. Lastly,
since the OBCOST tool uses the IPM model to calculate
incidence from prevalence and mortality data, prevalence
data have to be sufficiently smooth in order to prevent
generating negative incidences. When prevalence data
were not increasing monotonously, these data had to be
smoothed in order for the OBCOST software to work
properly. Slight deviations in the smoothness of the prev-
alence data were fixed by averaging the prevalence rate
causing the tool to err with the prevalence rate in the
previous age group, and using this average for both age
groups.
Sensitivity analyses
Sensitivity analyses were performed in several ways. First,
the sensitivity of the tool for missing disease data was
estimated by including estimations of these missing disease
data based on the data in the other countries in sensitivity
calculations. The missing diseases categories were esti-
mated by averaging data for the missing disease categories
from the other two countries. Second, sensitivity of the tool
to changes in disease costs was estimated by including
pharmaceutical costs for hypertension and diabetes in cost
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data for CZR. These pharmaceutical costs were not inclu-
ded in the cost of illness for CZR, but were provided
separately based on the Anatomical Therapeutic Chemical
(ATC) classification system. Third, sensitivity analyses
were performed with both of the previously described sit-
uations at the same time. Fourth, the sensitivity of the tool
to variations in BMI prevalence was estimated, since
studies have shown that self-reported BMI tends to differ
from measured BMI by overestimating BMI at the lower
end of the BMI scale (BMI\ 22) and underestimating
BMI at the higher end of the BMI scale (BMI[ 28) [19,
20]. The effect of these variations was estimated by
increasing BMI prevalence with 0.56 for preobesity and
1.16 for obesity [19, 20]. Lastly, the effect of exclusion of
different types of disease categories was estimated by
excluding various diseases one by one from all analyses.
Results
As could be expected, the proportion of males (49 %) and
females (51 %) in the population is the same for all three
countries. Table 1 shows population data and summarized
disease data for each country. The proportion of the pop-
ulation older than 55 years ranges from 28 % for NL to
33 % for GE. As can be seen in Fig. 2, which presents the
BMI distribution across age categories for the three coun-
tries, the prevalence of overweight increases from age 20 to
age 74. The absolute prevalence of overweight is highest
between the ages of 55 and 74. In NL, this prevalence
ranges from approximately 50 % for females to about
60 % for males, while in GE it rises to approximately 60 %
for females and 70 % for males. In CZR the prevalence of
overweight is highest, with almost 80 % for both sexes.
The summarized disease data in Table 1 do not show
major differences between countries except for diabetes
prevalence in CZR and osteoarthritis prevalence in GE,










Population aged[55 (%) 28 33 30
Disease prevalence/incidence (per 100 person years) in total
populationa
IHD (%) 10b 10b 9b
Stroke (%) 3b 5b 4b
Hypertension (%) 21b 29b 30b
Diabetes (%) 7b 6b 17b
Colon cancer (%) 0.15c 1b 0.15c
Breast cancer (%) 0.32c 1b 0.08c
Endometrial cancer (%) 0.02c 0.02c 0.02c
Kidney cancer (%) 0.07c 0.08c 0.12c
Osteoarthritis (%) 9b 20b 10b
a Summarized disease data are presented as provided by the different
countries and entered into the OBCOST tool in order to show the
flexibility of the tool in handling the differences between different
countries in collecting and registering data (e.g., the use of prevalence
or incidence rates for certain diseases)
b Disease prevalence
c Disease incidence (per 100 person years) Fig. 2 BMI distributions across age for each country
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which are both much higher than in the other countries.
Table 2 presents annual costs for all included diseases for
each country together with the (percentages of) costs that
can be attributed to preobesity, obesity or overweight in
total. Despite large differences in total annual costs and
costs per capita, the results show that between one-fifth and
a quarter of total disease costs can be attributed to over-
weight, with percentages ranging from 20 to 26 %. Fur-
thermore, the percentage of costs attributable to obesity
and preobesity is about the same. Figure 3 shows the per-
centages of costs that can be attributed to preobesity and
obesity for each disease separately, diabetes, endometrial
cancer and osteoarthritis being the three leading diseases
with the highest percentages of respectively about
50–60 %, about 38 % and about 25–55 %. In terms of
absolute attributable costs, the diseases with the highest
costs attributable to overweight are diabetes (€444 million,
€3.6 billion and €60 million for NL, GE and CZR
respectively), IHD (€267 million, €1 billion and €43 mil-
lion for NL, GE and CZR respectively) and osteoarthritis
(€142 million, €2 billion and €24 million for NL, GE and
CZR respectively).
The percentages of costs attributable to overweight
calculated here are percentages of total costs of included
diseases, as opposed to percentages of total annual health
care expenditures. Estimation of the percentage of total
health care costs that are attributable to overweight (based
on the costs of diseases included in this analysis) results in
percentages of 2.3 % for NL, 2.1 % for CZR and 3.7 % for
GE.
Sensitivity analyses
Table 3 shows the effects of various sensitivity analyses
compared with the original model. In the first analysis, the
missing disease categories endometrial cancer and kidney
cancer for GE and CZR respectively are added to the ori-
ginal model, which does not result in any changes. How-
ever, the model is sensitive to variations in cost data.
Inclusion of pharmaceutical costs for diabetes and hyper-
tension for CZR results in an increase of the percentage of
total costs attributable to overweight from 26.1 to 30.6 %.
Inclusion of both the estimations for kidney cancer and
these pharmaceutical costs lowers the percentage to 29.7 %
for CZR. Increases in BMI prevalence as described in the
fourth sensitivity analysis resulted in an increase of the
percentage of total disease costs attributable to overweight
of 0.7 % for NL and GE and of 0.6 % for CZR. Exclusion
of diseases as described in the last sensitivity analysis has
various effects, depending on the type of disease. Exclu-
sion of endometrial and kidney cancer does not result in
consequential changes of the percentage of costs attribut-
able to overweight. Exclusion of stroke increases the per-
centage of total costs attributable to overweight with 2.7 %
for NL, 3.1 % for GE and 3.6 % for CZR. Exclusion of
diabetes lowers the percentage of total costs that are
attributable to overweight with 5.2 % for NL, 6.5 % for GE
and 5.3 % for CZR.
Discussion
The estimated percentage of total costs of nine obesity-
related diseases attributable to overweight ranges from 20
to 26 % in this analysis. Main contributors to this high
percentage are diabetes, endometrial cancer and osteoar-
thritis. The present results are based on data provided by
different countries with their own ways of collecting and
registering data. This has some consequences for the
quality and comparability of the data entered into the tool.
Data for the eldest age groups were often not available.
Estimations were made by applying the rate of the last
available age group to all successive age groups. Since the
eldest age groups (85?) are very specific groups, these
assumptions are very precarious and can possibly bias the
results. Due to the assumptions made, exclusion of these
eldest age groups from this analysis had little effect on the
percentage of total disease costs attributable to overweight.
In general, the eldest age groups have a larger disease
burden compared with the younger age groups. However,
much of this disease burden is due to non-overweight-
related diseases, so a relatively smaller share of the disease
Table 2 Absolute costs and percentage of costs of included diseases attributable to overweight
Total costs in € Costs per
capita in €a
Costs due to preobesity in €
(% of total costs)
Costs due to obesity in €
(% of total costs)
Costs due to overweight in €
(% of total costs)
The Netherlands 6.029.469.861 476 657.302.148 (11) 528.386.496 (9) 1.185.688.644 (20)
Germany 38.737.666.667b 582 4.232.431.091 (11) 5.154.965.842 (13) 9.387.396.934 (24)
Czech Republic 763.339.408c 91 90.612.458
(12)
108.310.987 (14) 198.923.446 (26)
a For the population aged 20?
b Excluding endometrial cancer
c Excluding kidney cancer and pharmaceutical costs
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burden in the eldest age groups is attributable to over-
weight. Therefore, the percentage of disease costs attrib-
utable to overweight in the eldest age groups can be
expected to be relatively low and pull down the percentage
of total disease costs attributable to overweight. However,
due to the small size and relatively low absolute costs of
the eldest age groups (regarding the diseases included in
this analysis), this influence might not be significant.
Due to variations and uncertainties regarding the
included diseases, cost data and BMI data, various sensi-
tivity analyses were performed that yielded only small
effects. Since including estimations of missing data did not
change the percentages of total disease costs attributable to
overweight, slight deviations in the ICD-10 codes for
which disease data were provided can be expected to have
negligible effects as well. Inclusion of pharmaceutical costs
for CZR did result in a percentage change, suggesting that
differences in cost data can influence cost estimates. Cost
data are preferably based on the functional classification of
the SHA [17] in order to ensure maximal comparability.
However, many countries differ in their level of imple-
mentation of this classification [15, 21], which can result in
considerable bias in comparisons. Variations in self-
reported and measured BMI data are unlikely to bias
comparisons between countries, since sensitivity analyses
showed only a small effect on the percentage of total dis-
ease costs attributable to overweight.
This study uses a method in which current disease
prevalence data are used to estimate past incidence rates,
which in turn are used to calculate current prevalence rates
in a hypothetical population without overweight. However,
since BMI prevalence rates have changed over time [22],
the method should also apply past BMI prevalence rates to
past incidence rates in order to be completely accurate.
However, in order to do this, more complex methods are
needed. This undermines the aim of this tool. However, it
should be kept in mind that since BMI prevalence rates
may change with different dynamics in different countries
[23], this might affect the comparability of the results.
Some methodological issues are discussed according to
their potential influence as opposed to previous calcula-
tions. First, the results of this method will depend on the
number and type of diseases that are included in the cal-
culations; this will influence both absolute costs and
Fig. 3 Percentage of costs attributable to overweight for each disease, with preobesity and obesity presented separately
Table 3 Changes in percentage of total disease costs attributable to





Original (%) 19.7 24.2 26.1
All diseases equal (%) 19.7 24.3a 25.5b
All cost categories equal (%) 19.7 24.2 30.6c
Both equal (%) 19.7 24.3 29.7
Adjusted BMI (%) 20.4 24.9 26.7
Excluding various diseases (%)
Endometrial cancer 19.7 – 25.8
Kidney cancer 19.7 24.4 –
Osteoarthritis 19.1 23.2 24.2
Diabetes 14.5 17.7 20.8
Stroke 22.4 27.3 29.7
a Costs for endometrial cancer estimated based on costs from NL and
CZR
b Costs for kidney cancer estimated based on costs from NL and GE
c Pharmaceutical costs for hypertension and diabetes included
66 M. Lette et al.
123
percentage of costs attributable to overweight. Generally,
when more diseases are included, estimated absolute costs
attributable to overweight will increase. The estimated
percentage of costs attributable to overweight is strongly
dependent on the PAP of the included diseases. When
diseases have a low PAP (such as stroke), a relatively small
share of the costs of these diseases will be attributable to
overweight. Therefore, these diseases will lower the per-
centage of total costs of included diseases attributable to
overweight. On the other hand, diseases with a high PAP
(such as diabetes) will result in an increase of this
percentage.
Second, the percentages of costs attributable to over-
weight calculated by the OBCOST tool are percentages of
total costs of included diseases, as opposed to percentages
of total annual health care expenditures. Estimation of the
percentage of total health care costs that are attributable to
overweight (based on the costs of diseases included in this
analysis) results in percentages of 2.3 % for NL, 2.1 % for
CZR and 37 % for GE. This is in line with results found in
previous studies, where percentages were found ranging
from 2.1 % of total health care costs in Germany to 4.8 %
of total health care spending in the US [6–11].
Third, by using PAPs, the method assumes that over-
weight-related diseases are mutually exclusive. However,
overweight people often have multiple attributable diseases
at a time, and often interactions exist between these con-
ditions. The dynamics of these interactions are not reflected
in the relative risks used for the PAPs. When health care
provision for multiple diseases becomes more efficient (for
example, due to the implementation of the chronic care
model [24]), this will result in an overestimation of the
estimated costs attributable to overweight.
Furthermore, when interpreting the results of this study
it should be kept in mind that the presented costs consist of
direct (medical) costs attributable to overweight. They do
not take into account indirect costs such as production
losses due to morbidity, mortality or informal care. Inclu-
sion of indirect costs can lead to much higher estimates of
total costs attributable to overweight. A review by Trogdon
et al. (2008) [25] found absolute indirect costs of obesity
ranging between $448 million ($204 per obese person) in
Switzerland and $66 billion ($1,627 per obese person) in
the USA. In Canada, indirect costs attributable to over-
weight were estimated to be $5 billion, constituting 9.5 %
of total indirect costs (total indirect costs in this study
consisted of short- and long-term morbidity costs for 18
comorbidities, including the diseases included in this ana-
lysis) [9]. Estimations of indirect costs should be added up
to the estimated direct medical costs in order to determine
total costs attributable to overweight. The absolute costs
presented in this study will therefore be an underestimation
of the total costs attributable to overweight and obesity.
Practical implications
Since the OBCOST tool uses data that are supposed to be
generally available for many countries, the tool can be used
by any country where BMI data are available and where
health care expenditure data are available coded by disease.
When this is not the case, estimations can be made by using
foreign data. The standardized method of cost calculations
will lead to more comparable estimates of costs of over-
weight between countries. However, due to the flexible
nature of the tool, expansion of its functionality is sup-
ported should the user find this necessary. For instance, one
can include the nonmedical costs of disease or extend the
selection of diseases by adding other diseases known to be
associated with overweight [26].
Information about costs attributable to overweight is
important for establishing a case of preventive action [10].
By using a prevalence-based approach, this method is par-
ticularly suited for estimating the magnitude of the annual
economic burden attributable to overweight. However, it
does not provide information on the long-term conse-
quences of overweight and the value of specific interven-
tions that may lessen the burden of disease. To obtain this
kind of information, an incidence-based approach is more
appropriate, identifying what future lifetime costs would be
avoided if all new overweight cases would be eliminated
during a certain year. Successful prevention of overweight
will lead to a decrease in the percentage of health care costs
attributable to overweight, as a larger part of the health care
costs will be due to age-related diseases and not over-
weight-related diseases. However, for the effect of suc-
cessful prevention on total health care costs, also costs of
life years gained need to be taken into account. Generally,
successful prevention will result in an increase in life
expectancy, in which people will suffer from other diseases.
This will increase total health care costs in the long term.
However, because overweight is related to some low-mor-
tality but high-cost diseases such as osteoarthritis, the ratio
of cost savings due to reduced incidence of risk factor-
related diseases and the medical costs of life years gained is
more favorable for overweight prevention than for example
for smoking prevention [27]. These future costs, together
with the costs of preventive interventions themselves, are
relevant when cost calculations are performed in order to
support health care decision makers in formulating specific
health policies. However, if the aim is to use attributable
costs as an indicator of conditions because of past policies,
the prevalence-based approach is suitable. Furthermore,
data needed for an incidence-based approach are more
complex and often less readily available, which makes the
prevalence-based approach more applicable.
This tool can be relevant for several purposes. In the first
place, it can serve to increase knowledge as a long-term
Health care costs attributable to overweight calculated 67
123
monitoring instrument in order to keep track of changes in
the annual economic burden of overweight. Furthermore,
the tool could also be developed for other risk factors of
disease. This way, the tool can be used to monitor and
compare between costs attributable to different risk factors.
This kind of information could be helpful in determining
which risk factors or diseases are most costly and how to
distribute preventive resources.
Conclusion
The present study described a standardized methodology
for calculating health care cost attributable to overweight.
This methodology increases comparability between coun-
tries. Results show that for the three countries included,
roughly a quarter of the costs of included diseases are
attributable to overweight. Information about the costs of
overweight increases political awareness and emphasizes
the need for preventive action.
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